DRUG · Unmapped registry intervention
GZ17-6.02
Find medicine records ·
Find other trials using this name
Clinical trial
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
NCT03775525
Study summary
ClinicalTrials.govStudy Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Capecitabine
Normalized identity: capecitabine View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Advanced Cancerunresolved
Gastric Cancerverified · MONDO: gastric cancer
Breast Cancerverified · MONDO: breast cancer
Colo-rectal Cancerunresolved
Solid Tumorunresolved
Solid Carcinomaunresolved
Solid Carcinoma of Stomachunresolved
Cancer of Stomachverified · MONDO: gastric cancer
Lymphomaverified · MONDO: lymphoma
Sarcomaverified · MONDO: sarcoma
Interventions
GZ17-6.02DRUG
CapecitabineDRUG · verified · RxNorm: capecitabine
Sponsors & collaborators
Genzada Pharmaceuticals USA, Inc.lead sponsor
Translational Drug Developmentcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03775525 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.